1099-1069/asset/HON_left.gif?v=1&s=d87f3b2696ccc0dedb2d500a48bb5dc4ee9ac4e1)
1099-1069/asset/HON_right.gif?v=1&s=193f0d505463b12e551fb780235d2c9eaa727164)
Review
The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia
Article first published online: 9 DEC 2009
DOI: 10.1002/hon.931
Copyright © 2009 John Wiley & Sons, Ltd.
1099-1069/asset/cover.gif?v=1&s=4ed56ff6292a886bbae0f3c5a756507da24e8d15 "Hematological Oncology")
Additional Information
How to Cite
Owen, C., Fitzgibbon, J. and Paschka, P. (2010), The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematological Oncology, 28: 13–19. doi: 10.1002/hon.931
Publication History
- Issue published online: 15 MAR 2010
- Article first published online: 9 DEC 2009
- Manuscript Accepted: 11 SEP 2009
- Manuscript Received: 7 SEP 2009
- Abstract
- References
- Cited By
Keywords:
- WT1;
- mutation;
- acute myeloid leukaemia;
- prognosis
Abstract
Recurrent genetic aberrations are important predictors of outcome in acute myeloid leukaemia (AML). Numerous novel molecular abnormalities have been identified and investigated in recent years adding to the risk stratification and prognostication of conventional karyotyping. Mutations in the Wilms Tumour 1 (WT1) gene were first described more than a decade ago but their clinical significance has only recently been evaluated. WT1 mutations occur in approximately 10% of adult AML patients at diagnosis and are most frequent in the cytogenetically normal (CN) AML subgroup. These mutations appear to confer a negative prognostic outcome by increasing the risk of relapse and death. Mutation frequency is higher in pediatric patients and also appears to confer a negative impact on relapse and survival. Herein, we discuss the importance of WT1 mutations in AML. Copyright © 2009 John Wiley & Sons, Ltd.